A NEW STANDARD OF CARE
Our mission at PreciseDx® is to deliver objective, accurate and reliable reporting of key clinical information within hours, to improve comprehensive decision-making for patients affected by cancer.
PreciseDx allows cancer specialists to confidently formulate a comprehensive review of their patient's specific tumor, allowing for a more informed care plan.
94%
Negative Predictive Value*
98%
Reproducibility and Repeatability**
99%
Intra-Lab Concordance**
*Fernandez, G., Prastawa, M., A.S. et al. Breast Cancer Research 2022
**PreciseDx's "Analytical Validation of a Digital Breast Cancer Test Predicting Recurrence in Early-Stage Breast Cancer", Clinical Breast Cancer, Nov 2023
The science
We’ve long known that the secrets of cancer can be seen directly in their cellular structure, but in the past we could only look at that structure qualitatively. PreciseDx changes that.
Our study of more than 2,000 breast cancer cases* identified 7 morphologic factors that can be visualized in pathology slides and 4 clinical features that, together in our proprietary algorithm, best predict recurrence at 6 years.
The result is the Morphology Feature Array®. Applied to existing tissue slides, it produces a single Risk Score between 0 and 100, which accurately and consistently stratifies patients into two cohorts based on their tumor’s risk of recurrence.
Low risk patients have, on average, a 6% recurrence risk, while high risk patients have, on average, a recurrence risk of 24%.
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Nov 20, 2024
World-Renowned Breast Cancer Oncology and Pathology Experts to Advise Company on the Advancement of its AI-Powered PreciseBreastTM Risk of Recurrence Assessment and Product Portfolio
See More
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Aug 21, 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
See More
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Aug 2, 2024
As AI-Based Diagnostics Proliferate, Stakeholders Strive for Regulation Without Stifling Innovation
See More
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Jul 23, 2024
PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics
See More
Contact us today to learn more about PreciseBreast.
